论文部分内容阅读
[目的]探讨新辅助化疗对宫颈癌患者外周血 Treg 细胞、血清 TGF-β1、VEGF 水平及组织 VEGF、CD105表达的影响.[方法]选取2014年3月至2017年3月期间在本院进行手术治疗的97例宫颈癌(Uterine Cervical Cancer,UCC)患者为研究对象,所有患者均采用新辅助化疗;以70例健康人为健康对照组(Healthy con-trol,HC).流式细胞仪检测三组外周血 Treg/CD4+细胞比例,Elisa 法检测血清 TGF-β1、VEGF水平,免疫组化法检测癌组织 VEGF、CD105表达.[结果]UCC 组新辅助化疗前外周血 Treg/CD4+细胞比例、TGF-β1、VEGF水平高于 HC组,其差异具有统计学意义(P <0.05).新辅助化疗后 UCC 组患者外周血 Treg 细胞比例、血清TGF-β1、VEGF水平均较化疗前降低,差异具有统计学意义(P <0.05).化疗后 UCC 组患者癌组织标本中VEGF及CD105表达水平较化疗前明显降低,差异具有统计学意义(P <0.05).Pearson 相关性分析表明, VEGF及CD105在 UCC中的表达呈正相关关系(r= 0.557,P =0.032).[结论]新辅助化疗可降低 UCC 患者外周血Treg/CD4+细胞比例,减少TGF-β1的释放,进而降低肿瘤病灶中CD105及 VEGF的表达,抑制肿瘤血管生成,有利于缩小肿瘤病灶.“,”[Objective]To study the influence of neoadjuvant chemotherapy on the ratio of Treg/CD4 cells in the peripheral blood,serum levels of TGF-β1 and VEGF,and the expression of VEGF and CD105 in tumor tissues.[Meth-ods]A total of 97 patients with uterine cervical cancer(UCC)who were treated in our department from Mar 2014 to Mar 2017 were enrolled in this study(UCC group);all patients received neoadjuvant therapy.Meanwhile,70 healthy women were included in the control group (HC group).The ratio of Treg/CD4+ cells was measured by the flow cytometry as-say,;serum levels of TGF-β1 and VEGF were detected by ELISA assay,and the expression of VEGF and CD105 in the tumor tissue was evaluated by the immunohistochemistry.[Results]Before the neoadjuvant therapy,the ratio of the pe-ripheral Treg/CD4 cells and the serum levels of TGF-β1 and VEGF were significantly higher in the UCC group than in the HC group(P <0.05).The ratio of Treg/CD4 cells and the serum levels of TGF-β1 and VEGF were significantly de-creased after the neoadjuvant therapy(P <0.05).The expression of VEGF and CD105 in the tumor tissue of the UCC group significantly decreased after neoadjuvant therapy(P <0.05).A positive correlation between VEGF and CD105 ex-pression in the UCC tissue was found by the Pearson correlation analysis(r=0.557,P =0.032).[Conclusion]Neoadju-vant therapy can decrease the ratio of the peripheral Treg/CD4+ cells,reduce the release of TGF-β1,and downregulate the expression of CD105 and VEGF in the UCC tissue,thereby inhibiting angiogenesis and improving remission.